BARDA is seeking additional proposals for products that potentially could treat or illness and injury from acute radiation syndrome
, as well as improved diagnostic tools to measure the radiation dose a person has absorbed after a nuclear denotation or radiation accident.
Our ultimate goal is to develop safe and effective human therapeutics that could be used against acute radiation syndrome
Her research has spanned drug discovery, preclinical development, manufacturing and clinical development in indications such as acute radiation syndrome
, inflammation, infectious disease, cancer and cancer supportive care.
Soligenix is also developing OrbeShield(TM) for the treatment of gastrointestinal acute radiation syndrome
(GI ARS) under a BARDA contract award valued up to $26.
Support for OrbeShield(TM) product development is being provided under a CBRN program to advance technologies and products to treat acute radiation syndrome
Immediately after exposure, the most critical components of acute radiation syndrome
are the hematopoietic (bone marrow) and early-onset gastrointestinal (GI) syndromes because symptoms begin very quickly and can be lethal.
WASHINGTON -- Two contracts for advanced development of drugs to treat skin and lung injuries associated with acute radiation syndrome
(ARS) were awarded this week by the U.
In response to an invitation from the Biomedical Advanced Research and Development Authority (BARDA), we submitted a contract proposal to support the development of OrbeShield (TM) for the treatment of gastrointestinal acute radiation syndrome
(GI ARS), which if awarded, has the potential to be a multi-million dollar contract.
OTC: AOLS), today announced that it has been invited to deliver an oral presentation on AEOL 10150, the Company's novel, broad-spectrum catalytic antioxidant compound that reduces oxidative stress, inflammation, and subsequent tissue damage-signaling cascades resulting from radiation exposure in development for use in oncology, where it will be used in combination with radiation therapy, and as a medical countermeasure against the pulmonary sub-syndrome of acute radiation syndrome
("Pulmonary Acute Radiation Syndrome
" or "Lung-ARS") as well as the gastrointestinal sub-syndrome of acute radiation syndrome
("GI-ARS"), both caused by exposure to high levels of radiation due to a radiological or nuclear event, at the Biomedical Advanced Research and Development Authority (BARDA) Industry Day.
This submission supports a potential multi-year, multi-million dollar contract to develop OrbeShield (TM)(oral beclomethasone 17,21-dipropionate or oral BDP) as a medical countermeasure (MCM) for the treatment of gastrointestinal acute radiation syndrome
Aside from the cutaneous injury, acute radiation syndromes
affect the hematopoietic, cardiovascular, gastrointestinal, and central nervous systems, starting with a prodromal phase that typically consists of nausea, vomiting, and diarrhea.